

# ISPOR Europe 2019

The leading European Conference for Health Economics and Outcomes Research

## PROGRAM

**2-6 November 2019**  
**Copenhagen, Denmark**

***Digital Transformation of  
Healthcare: Changing Roles  
and Sharing Responsibilities***

 **ISPOR**



Join more than 5000 global healthcare leaders at ISPOR Europe 2019 – an energizing meeting ground for sound science, robust methodology, relevant policy discussions, and multistakeholder perspectives.

ISPOR Europe 2019 in Copenhagen offers opportunities to debate value in healthcare beyond cost-containment and short-term interventions – strategic perspectives, scientific validity and diverse global experiences. During the five days of the conference you will:

**Learn** about digitization, digitalization, and digital transformation in healthcare and explore their impact on HEOR.

**Present and debate** your research results and ideas in an open and neutral environment.

**Advance** your career while staying current on emerging trends and attending short courses.

**Engage** with recognized global experts and network with colleagues, collaborators, and clients.

ISPOR is the leading scientific and educational organization for HEOR and its use in healthcare decision-making. The ISPOR sphere of influence engages global leaders in the world-wide HEOR community, including policy makers, regulators, researchers, academicians, health technology developers, payers, healthcare providers, and patient groups. The diversity in work environments, and regional and international scope of attendance provide excellent networking opportunities and stimulating discussions and debate.

## #ISPOREurope

### Trending topics:

- Real-World Evidence
- Digital Health
- Health Technology Assessment
- Machine Learning and Artificial Intelligence
- Clinical Outcomes Assessment
- Patient Preferences
- Biosimilars
- Rare Disease
- Gene Therapies and Curative Treatments
- Medical Devices
- Health State Utilities
- Oncology
- Patient Engagement
- Patient-Reported Outcomes
- Big Data Analysis
- Drug Pricing
- Value Assessment
- Alternative Payment Models
- Methods and Modeling for Decision-Making
- Predictive Analytics
- Universal Health Coverage

**Register by 24 September and SAVE!**

**[www.ispor.org](http://www.ispor.org)**

## Make the most of ISPOR Europe 2019!

### SPOTLIGHT SESSIONS

Join in the discussion at ISPOR's spotlight sessions developed to highlight and advance areas of innovation in HEOR for the ISPOR community.

#### Monday, 4 November, 14:15 - 15:15

##### Transparency in Real-World Evidence – Time for a Unified Approach

This session will provide an overview of the history and goals of the RWE Transparency Initiative and why it is timely, as well as its work to date. This will include a summary of the white paper and its responses. It will cover fundamental aspects of this issue including credibility vs. transparency, characteristics of studies recommended for registration (ie, HETE studies), the importance of reporting, and replicability and the totality of evidence.

#### Monday, 4 November, 15:45 - 16:45

##### Genomics in the Future of Health – The Road to Better Outcomes?

The accelerating development in digital possibilities opens for better understanding of our biology where the progress in the field of genomics (and multiomics) has opened for new insight and understanding of health and disease. Personalized health is built on genomics and is seen as a necessary change for future health systems. At the same time, a host of questions need to be addressed to ensure that the new knowledge and tools bring about better outcomes. This session will bring together the two worlds of HEOR and clinical genomics to explore how implementation of these transformational technologies can be better guided by evidence. The current achievements of clinical genomics and approaches to assessing the costs and benefits of these emerging technologies will be reviewed followed by discussion on how health economics and outcomes research can be better used to influence how genomics is rolled out in the clinic.

#### Tuesday, 5 November, 15:45 - 16:45

##### The Evolving Demands for Medical Device Evidence Development: What the Future Holds

This expert panel will review the latest issues in medical device evidence requirements, with discussion of several case study examples. Key issues to be addressed include the evolution of EUnetHTA joint assessments and how they are applied by EU member countries, the impact of new CE mark-related evidence requirements, and how medical device firms should work to bridge the divide between country level requirements for Health Technology Assessment and regulatory study requirements. Panel will include HTA experts from national bodies, along with industry experts.

### FEATURED SESSION: Tuesday, 5 November, 14:15 - 15:30

#### Ideas Lab! New Insights to Improve Decision Making for Health Globally

ISPOR's Ideas Lab – an intensive, interactive and free-thinking environment where a diverse group of HEOR stakeholders will discover and discuss new insights to improve decision making for health globally. Participants are encouraged to come together to explore, challenge, and co-create novel, and potentially transformative, approaches (“aha!” moments) to HEOR. Topics for discussion will include new thinking on “social determinants” and alternative perspective on the “O” and the “E” in HEOR, sustainability index to futureproof healthcare, and next generation HTA for complex and personalized combinations of health technologies. The session is designed to fuel original views and fresh perspectives and to trigger and strengthen innovative thinking and the spirit of discovery in the HEOR community.

### NETWORKING

#### Connect with ISPOR members, colleagues, collaborators, and clients.

- Expand your professional network with more than 5000 international healthcare leaders and stakeholders throughout the conference, while attending educational sessions, the poster exhibit hall, and group meetings.
- Schedule meetings with experts, clients, and other attendees via the conference app and web platform (available approximately 1 month prior to the conference).
- Engage in session discussions with colleagues, then continue the conversation between sessions.

### ISPOR GROUPS

#### Collaborate with members of your ISPOR groups.

**ISPOR Regional Groups (Chapters, Networks, and Consortia):** Join the educational, research, and policy-related activities of these groups and meet other HEOR professionals from your region of the world.

**ISPOR Scientific and Health Policy Groups (Task Forces, Special Interest Groups, and Council Working Groups):** Collaborate with members of these groups and participate in the development of ISPOR knowledge products, such as ISPOR Good Practices for Outcomes Research Task Force Reports, manuscripts for *Value in Health*, and online tools used by decision makers and researchers around the world.

**New Professionals:** The ISPOR staff and New Professional Steering Committee have organized a few activities geared toward New Professionals for ISPOR Europe. Attend the “Career Advice Across the Globe” event, which touches on a different career-related topic for each conference. The event, being hosted for the second time in Europe, aims to provide a global perspective for those who are new to the field of HEOR. New Professionals are invited to network with their peers, and more seasoned HEOR professionals, during the ISPOR Global Networks Reception. New Professionals are also encouraged to stop by the various ISPOR Booth events, that focus on membership, to highlight opportunities to get further involved and maximize your ISPOR experience.

### POSTER EXHIBIT HALL

Along with more than 2000+ posters available for viewing, over 100 exhibitors and sponsors will be present to help you discover solutions and discuss the trends in HEOR. Make time in your schedule to visit the new addition of the ISPOR Exhibitor HEOR Theater also located in the Hall. These 30-minute insightful, informative, and educational sessions presented by Exhibiting Companies are open to all delegates.

## Plenary Sessions Featured at ISPOR Europe 2019\*

### FIRST PLENARY SESSION: Monday, 4 November, 9:00 - 10:30

#### Healthcare Digitalization: Instant, On Demand, and Always Connected

Rapid change is affecting health care systems in real-time - major changes relate not only to technology but also to the way care is organized and delivered. The paradigm is shifting from treating illness to sustaining well-being making individualized care even more relevant. The panel will explore the objectives, incentives and aspirations of the new players in digital transformation and how the roles of traditional stakeholders are changing, particularly how to strengthen the effectiveness of the change efforts to deliver the desired results.

*Moderator:* **Bogi Eliassen**, Copenhagen Institute for Futures Studies, Copenhagen, Denmark

*Speakers:* **Ernst Kuipers, MD**, Erasmus MC University Medical Center, Rotterdam, The Netherlands; **Peter Knox, MPP**, The Life Raft Group, Wayne, NJ, USA; **Alexandra Goncalves, MD, PhD, MSc**, Philips Healthcare, Cambridge, MA, USA

### SECOND PLENARY SESSION: Tuesday, 5 November, 9:00 - 10:30

#### Shaping the Digital Healthcare System

In this session we will explore how the key 'actors' in healthcare systems are adapting to the technological developments to deliver more productive, more effective and more personal care for patients. Each speaker will outline the new policies, processes and skill sets they are developing to deliver this digital healthcare system change and debate what it takes to deliver the changes required at pace and at scale for the benefit of patients.

*Moderator:* **Petra Wilson**, Health Connect Partners, Brussels, Belgium

*Speakers:* **Deborah James**, Author, Columnist & Patient Advocate, London, UK; **Thomas Senderovitz**, Danish Medicines Agency, Copenhagen, Denmark

### THIRD PLENARY SESSION: Wednesday, 6 November, 11:15 - 12:30

#### Big Healthcare Data: Endless Opportunities for Research and Learning

Big data present a tremendous opportunity for the measurement and reporting of quality in healthcare. However, such high volume and high-variety information demand innovative forms of information processing to ensure enhanced insight and decision making. The opportunities are vast and the challenges are great; new methods are needed to harness the potential for these data to have real impact. The aim of this plenary session is to inspire the audience with examples from the experts who are using these tools not only for research but driving learning at the healthcare system level.

*Moderator:* **Dorte Gyrd-Hansen, PhD, MSc**, University of Southern Denmark, Odense, Denmark

*Speakers:* **Ziad Obermeyer, MD**, University of California-Berkeley, Berkeley, CA, USA; **Laura A. Hatfield, PhD**, Harvard Medical School, Boston, MA, USA

\* Plenary speakers as of press time.

### Thank you to the following ISPOR 2019 Supporters and Sponsors:

*(Sponsors as of August 2019)*

#### Gold Level:

Avalere

Evidera

Pharmerit

#### Silver Level:

Certara

Ingress

#### Bronze Level:

Huron

Kantar

RTI Health Solutions

### Interested in becoming an Event Sponsor?

Visit <https://www.ispor.org/Europe2019sponsorship> for available opportunities.

## CONFERENCE PROGRAM COMMITTEE

ISPOR thanks the Conference Program Committee for its contributions in developing the scientific community's leading HEOR program.

### PROGRAM COMMITTEE CO-CHAIRS

**Dorte Gyrd-Hansen, PhD, MSc**, University of Southern Denmark, Odense, Denmark

**Carole Longson, PhD**, Association of the British Pharmaceutical Industry, London, UK

**Hans Severens, PhD**, Erasmus University Rotterdam, Rotterdam, The Netherlands

### RESEARCH COMMITTEE CO-CHAIRS

**Murtuza Bharmal, PhD**, EMD Serono, Rockland, MA, USA

**Robert Hettle**, AstraZeneca, Cambridge, UK

**Janine van Til, PhD**, University of Twente, The Netherlands

**Aleksandra Torbica**, Bocconi University, Milano, Italy

### ISSUE PANEL REVIEW COMMITTEE CO-CHAIRS

**Linus Jönsson**, H. Lundbeck A/S, Valby, Denmark

**Katarzyna Kolasa, PhD**, Kozminski University, Warsaw, Poland

**Jamie O'Hara**, HCD Economics, Daresbury, UK

### WORKSHOP REVIEW COMMITTEE CO-CHAIRS

**Alima Almayiyeva**, Kazakh Agency for Health Technology Assessment, Nur-Sultan, Kazakhstan

**Andrew Lloyd**, Acaster Lloyd Consulting Ltd., London, UK

**Carme Pinyol, MD, PhD, MSc**, Pierre Fabre, Barcelona, Spain

## Pre-Conference Short Course Program

**Learn. Apply. Advance. Attend any session, including one of our 9 NEW courses!**

The ISPOR HEOR Short Course Program, offered in conjunction with ISPOR conferences around the world as a series of 4- and 8-hour training courses, is designed to enhance your knowledge in 7 key topic areas (“tracks”) related to HEOR. Short courses (many with hands-on training opportunities) range from introductory to experienced and are taught by leading experts in the field.

Select courses require use of your personal laptop.

**Short Courses are offered Saturday, 2 November and Sunday, 3 November in the following topic areas:**

### Health Policy & Regulatory

Elements of Pharmaceutical/Biotech Pricing

**NEW!** US Payers — Understanding the Healthcare System™

Risk-Sharing/Performance-Based Arrangements for Drugs and Other Medical Products

**NEW!** Market Access & Value Assessment of Medical Devices

Risk-Sharing/Performance-Based Arrangements in Central & Eastern Europe: Implementation of Managed Entry Agreements

Reimbursement Systems for Pharmaceuticals in Europe

### Methodological & Statistical Research

Introduction to Modeling

**NEW!** Fitting the Structure to the Task: Choosing the Right Dynamic Simulation Model to Inform Decisions about HealthCare Delivery

Pharmacoeconomic Modeling – Applications

Analysis of Longitudinal Data: Fixed and Random Effects Models

Bayesian Analysis: Overview and Applications

**NEW!** Probabilistic Graphical Models with OpenMarkov, an Open-Source Tool

Understanding Survival Modeling With Application to HTA

**NEW!** Creating Natural, Flexible Models with DICE Simulation

Advanced Methods for Addressing Selection Bias in Real-World Effectiveness and Cost-Effectiveness Studies

### Health Technology Assessment

Introduction to Health Technology Assessment

Using Multi-Criteria Decision Analysis in HealthCare Decision Making: Approaches & Applications

Multi-Criteria Support Systems for Group Decision Making

### Patient-Centered Research

Introduction to Patient-Reported Outcomes Assessments

Mapping to Estimate Utility Values From Non-Preference Based Outcome Measures: Part 1

**NEW!** Mapping to Estimate Utility Values from Non-Preference Based Outcome Measures: Part 2

**NEW!** Health State Utility (HSU) Recommendations for Identification and Use of HSU Data in Cost-Effectiveness Modeling

### Study Approaches

Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources

Meta-Analysis and Systematic Literature Review

Use of Propensity Scores in Observational Studies of Treatment Effects

Network Meta-Analysis in Relative Effectiveness Research

### Real-World Data & Information Systems

**NEW!** Why all the Hype? Nordic Data Explained

Tools for Reproducible Real-World Data Analysis

**NEW!** Digital Real-World Evidence Generation Approaches in Rare Diseases and Oncology

### Economic Evaluation

Introduction to Health Economics and Outcomes Research

Statistical Methods for Health Economics & Outcomes Research

Alternative Economic Assessment for Expressing Healthcare Value and Informing Resource Allocation Decisions

Cost-Effectiveness Analysis Alongside Clinical Trials

Transferability and Relevance of Cost-Effectiveness Data Between Countries

Budget Impact Analysis I: A 6-Step Approach

Budget Impact Analysis II: Applications and Design Issues

Value of Information (VOI) Analysis

### SHORT COURSE FEES

#### ALL-DAY COURSES

*Through 24 September 2019*

Standard: \$920 (€800)

Clinical/Government/  
Academia: \$680 (€591)

Full-Time Students/Patient  
Representatives: \$290 (€252)

*After 24 September 2019*

Standard: \$1,020 (€887)

Clinical/Government/  
Academia: \$780 (€678)

Full-Time Students/Patient  
Representatives: \$340 (€296)

#### HALF-DAY COURSES

*Through 24 September 2019*

Standard: \$460 (€400)

Clinical/Government/  
Academia: \$340 (€296)

Full-Time Students/Patient  
Representatives: \$145 (€126)

*After 24 September 2019*

Standard: \$510 (€443)

Clinical/Government/  
Academia: \$390 (€339)

Full-Time Students/Patient  
Representatives: \$170 (€148)

**SEPARATE SHORT COURSE REGISTRATION IS REQUIRED.**

## Conference Program\*

### Saturday 2 November

8:00 – 17:00 **SHORT COURSES**  
(Separate registration required)

17:30 – 18:30 **EDUCATIONAL SYMPOSIUM**  
Sponsorship available! Please contact [sponsor@ispor.org](mailto:sponsor@ispor.org) for details

18:45 – 19:45 **EDUCATIONAL SYMPOSIUM**  
Sponsorship available! Please contact [sponsor@ispor.org](mailto:sponsor@ispor.org) for details

### Sunday 3 November

8:00 – 17:00 **SHORT COURSES**  
(Separate registration required)

17:30 – 18:30 **EDUCATIONAL SYMPOSIUM**  
How HTA Methodology and Evaluation Framework Should Adapt to Ensure Patient Access to Cell and Gene Therapies? (Sponsored by Novartis)

18:45 – 19:45 **EDUCATIONAL SYMPOSIUM**  
Indication Based Pricing: Aligning Incentives and Value to Improve Patient Access (Sponsored by London School of Economics and Political Science)

19:45 – 21:00 **ISPOR STUDENT & FACULTY ICEBREAKER RECEPTION**

### Monday 4 November

7:15 – 8:15 **EDUCATIONAL SYMPOSIUM**  
(Sponsored by Analysis Group)

8:30 – 10:30 **WELCOME AND FIRST PLENARY SESSION**  
**HEALTHCARE DIGITALIZATION: INSTANT, ON DEMAND, AND ALWAYS CONNECTED**

10:30 – 19:30 **POSTER AND EXHIBIT HALL HOURS**

10:30 – 14:00 **RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 1**

11:00 – 12:00 **BREAKOUT SESSION 1**  
**IP1:** Evaluating Digital Health Technologies: Why, What, and How?  
**IP2:** Is Delayed Access Due to Issues of HTA Capacity a Necessary Reality or an Unacceptable Problem?  
**IP3:** Fake or Novel Elements of Value?  
**P1:** Artificial Intelligence Studies  
**P2:** Patient Reported Outcomes & Quality of Life Studies  
**W1:** Translating Oncology Clinical Trial Endpoints to Real-World Data for Decision Making  
**W2:** Risk of Bias in Systematic Reviews with Cost and Cost-Effectiveness Outcomes

11:00 – 12:00 **ISPOR STUDENT RESEARCH SPOTLIGHT**

12:00 – 13:30 **LUNCH IN THE POSTER AND EXHIBIT HALL**

12:30 – 13:30 **EDUCATIONAL SYMPOSIUM**  
Capturing Multi-Stakeholder Perspectives on Assessing the Long Term Clinical Benefit of Cancer Immunotherapy  
(Sponsored by Bristol-Myers Squibb)

13:00 – 14:00 **POSTER AUTHOR DISCUSSION HOUR – SESSION 1**

14:15 – 15:15 **SPOTLIGHT SESSION**  
SP1: Transparency in RWE — Time for a Unified Approach

14:15 – 15:15 **BREAKOUT SESSION 2**  
**IP4:** Time for Change? Has the Time Come for the Pharma Industry to Accept Modest Prices?  
**P3:** Reimbursement & Access Policy Research  
**W3:** Demystifying Machine Learning: Why Being Open to It? When We Found It Useful  
**W4:** PRO Data Are Relevant Endpoints for HTA Assessment: Cui Bono

14:30 – 15:30 **ISPOR NEW PROFESSIONAL EVENT: CAREER ADVICE ACROSS THE GLOBE**

15:30 – 19:00 **RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 2**

15:45 – 16:45 **SPOTLIGHT SESSION**  
SP2: Genomics in the Future of Health — The Road to Better Outcomes?

15:45 – 16:45 **BREAKOUT SESSION 3**  
**IP5:** Are We There Yet? Using RWD for Regulatory-Grade External Control Arms  
**IP6:** Is Indication-Based Pricing Feasible and/or Beneficial for Society?  
**P4:** New Frontiers in Oncology Cost Studies  
**W5:** Do Innovative Technologies Require Innovative Appraisal Techniques? Case Studies from Recent HTA's in the UK, US, and Japan

17:00 – 18:00 **BREAKOUT SESSION 4**  
**IP7:** Considerations for Analyzing Real-World Genomics Data – The Value, Risks & Precautions  
**IP8:** Survival Extrapolation Approaches: New Era, New Methods?  
**P5:** Adherence, Persistence and Compliance Studies  
**P6:** Methodological and Conceptual Studies  
**W6:** Real-World Evidence in the Context of Health Technology Assessment  
**W7:** Using Patient Preference Data to Support Reimbursement and Pricing Decisions: Current Practice, Opportunities and Challenges  
**W8:** Improving Efficiency in HTA: The Role of Open Source Models and More Advanced Software Choice

18:00 – 19:00 **POSTER AUTHOR DISCUSSION HOUR – SESSION 2**

\* Program is subject to change.

**18:00 – 19:30 WELCOME RECEPTION IN THE POSTER AND EXHIBIT HALL**

**18:15 – 19:15 EDUCATIONAL SYMPOSIUM**

How Can Value Assessment Principles Be Applied to Support Access to Innovative Medicines in the Middle East and North Africa (MENA) Region? *(Sponsored by Sanofi)*

**19:30 - 21:00 ISPOR CENTRAL AND EASTERN EUROPE (CEE) CONSORTIUM RECEPTION**

**Tuesday 5 November**

**7:30 – 8:30 EDUCATIONAL SYMPOSIUM**

*(Sponsored by MSD)*

**8:45 – 10:30 WELCOME AND SECOND PLENARY SESSION SHAPING THE DIGITAL HEALTHCARE SYSTEM**

**10:30 – 14:00 RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 3**

**10:30 – 19:30 POSTER AND EXHIBIT HALL HOURS**

**11:00 – 12:00 BREAKOUT SESSION 5**

**IP9:** Transparency in RWE — Can We Navigate the Key Challenges?

**IP10:** How Can We Create Headroom for High-Value Care by Increasing Efficiency in Health Systems?

**IP11:** Cross-Border Collaboration on Availability of Pharmaceuticals in Europe — What, Why and What If?

**P7:** Clinical Outcomes Assessment Studies

**P8:** Infectious Disease Studies

**W9:** Estimating the Opportunity Cost-Based Cost-Effectiveness Threshold: Empirical Approaches and the Policy Challenges for Payers

**W10:** Patient Engagement in Health Research: Value of Lessons Learned in HTA and Possibilities for Cross-Context Transfer of Experience

**12:00 – 13:30 LUNCH IN THE POSTER AND EXHIBIT HALL**

**12:30 – 13:30 EDUCATIONAL SYMPOSIUM**

*(Sponsored by Xcenda)*

**13:00 – 14:00 POSTER AUTHOR DISCUSSION HOUR – SESSION 3**

**14:15 – 15:30 NEW FEATURED SESSION ISPOR IDEAS LAB**

**14:15 – 15:15 BREAKOUT SESSION 6**

**IP12:** A Formal System for Using Real-World Evidence to Revisit the HTA Decision: More Trouble Than It's Worth?

**IP13:** Should Gene Therapies be Exempt from HTA Scrutiny?

**P9:** Stated Preference & Patient Satisfaction Research

**W11:** Looking Beyond Statistical Adjustment to Untangle the Effects of Subsequent Treatments Selected by Investigators in Oncology Trials

**15:30 – 19:00 RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 4**

**15:45 – 16:45 SPOTLIGHT SESSION**

**SP3:** The Evolving Demands for Medical Device Evidence Development: What the Future Holds

**15:45 – 16:45 BREAKOUT SESSION 7**

**IP14:** Do We Still Need Randomized Controlled Trials?

**P10:** Cardiovascular & Diabetes Disorder Studies

**W12:** Is There a Systematic Methodology for Choosing Trial Endpoints That Incorporates Patients' Perspectives? What Might It Look Like?

**W13:** Application of Existing and Novel Network Meta-Analysis Methodologies: Appropriateness for HTA Purposes

**17:00 – 18:00 BREAKOUT SESSION 8**

**IP15:** Reduction of Bias or a Burden? The Use of Individual-Patient Models for Submission to HTA Authorities

**IP16:** Can and Should Evidence/Preferences Collected from Patients Tilt the Board in Favor of Accepting a New Technology?

**IP17:** Is Digital Health Interoperability Ensured for Research Purposes?

**P11:** Value Assessment of Medical Technology

**P12:** Neurological Disorders Studies

**W14:** A Novel Approach to Improving Our Understanding of the Burden of a Rare Disease: The Use of Opportunistic Retrospective Qualitative Analysis of Public Responses to Highly Specialized Technology Appraisal

**W15:** Cost-Effectiveness with Binding Budgets: Bad Medicine, Bad Economics, Neither or Both?

**18:00 – 19:00 POSTER AUTHOR DISCUSSION HOUR – SESSION 4**

**18:00 – 19:30 NETWORKING RECEPTION IN THE POSTER AND EXHIBIT HALL**

**18:15 – 19:15 EDUCATIONAL SYMPOSIUM**

*Sponsorship available! Please contact [sponsor@ispor.org](mailto:sponsor@ispor.org) for details*

**Wednesday 6 November**

**7:15 – 8:15 EDUCATIONAL SYMPOSIUM**

*Sponsorship available! Please contact [sponsor@ispor.org](mailto:sponsor@ispor.org) for details*

**8:30 – 9:30 BREAKOUT SESSION 9**

**IP18:** Value vs Value Traps: How to Control Prices for Highly Effective but High-Priced Therapies?

**IP19:** How Effective Are Managed Access Agreements as a Vehicle for Earlier Reimbursement in the Presence of Uncertainty? Lessons from the New Cancer Drugs Fund

**IP20:** Subscription-Based Model for Drug Reimbursement – a Fad or the Future?

**P13:** Cost-Effectiveness Studies

**P14:** New Frontiers in Health Technology Assessment Research

**W16:** Including Caregiver/Family Member Quality of Life in Economic Evaluations – Your Questions Answered

**W17:** Using Patient Preference Data to Support Clinical Trial Design: Current Practice, Opportunities and Challenges

**9:30 – 14:00 POSTER AND EXHIBIT HALL HOURS**

**9:30 – 14:00 RESEARCH POSTER PRESENTATIONS VIEWING – SESSION 5**

**9:45 – 10:45 BREAKOUT SESSION 10**

**IP21:** HTA'S Next Top Model: Medicines with Tumor-Agnostic Indications

**IP22:** Which Is the Way Forward for Health Technology Assessment of Interventions with External Benefits? Extended Cost-Effectiveness Analysis vs Cost-Benefit Analysis

**IP23:** Valuing Health in Children – Where Are We Now, and What Further Work Is Needed?

**P15:** Comparative Effectiveness or Efficacy Studies

**P16:** Expanding Horizon of Outcome Studies in Oncology

**W18:** Considering the Applicability of Guidance for Expert Elicitation in Healthcare Decision Making

**W19:** Nordic Registries in Safety Studies and Outcome Research: Using Real-World Evidence Advantages and Challenges of Pooling Register Data from Denmark, Sweden, Finland and Norway

**11:00 – 12:30 WELCOME AND THIRD PLENARY SESSION**

**BIG HEALTHCARE DATA: ENDLESS OPPORTUNITIES FOR RESEARCH AND LEARNING**

**12:30 – 13:45 LUNCH IN THE POSTER AND EXHIBIT HALL**

**12:45 – 13:45 POSTER AUTHOR DISCUSSION HOUR – SESSION 5**

**12:45 – 13:45 EDUCATIONAL SYMPOSIUM**

Value-Based Renal Care in Europe (*Sponsored by Baxter*)

**14:00 – 15:00 BREAKOUT SESSION 11**

**IP24:** Cost Utility Analysis or Cost Benefit Analysis for the Economic Evaluation of Nutrition Interventions?

**P17:** Real-World Data & Information Systems

**P18:** Treatment Patterns & Guidelines Studies

**W20:** A Quantitative Benefit-Risk Assessment by Applying the Principles of the European Medicines Agency Benefit Risk Assessment Framework and the Publicly Available, Open Source Tool ADDIS: A Hands-on Workshop

**W21:** Early HTA Advice: A Review of the Requirements and Opportunities to Achieve Collaborative and Efficient Dialogue

**W22:** Health Technology Appraisal Methods and Process for Antibiotics: Developments in the UK and Implications for Europe

**W23:** Qualitative Research for Discrete Choice Experiments (DCE): Towards Defining Gold Standards

*\* Program is subject to change.*

## Conference Registration Fees

	<i>Early Registration Deadline: 24 September 2019 Thru 24 September</i>		<i>After 24 September</i>	
	<b>Member</b>	<b>Non-member</b>	<b>Member</b>	<b>Non-member</b>
Standard	\$1120 (€974)	\$1345 (€1170)	\$1270 (€1104)	\$1495 (€1300)
Clinical Practitioners (Clinical Practice, Hospital)	\$885 (€770)	\$1110 (€965)	\$1035 (€900)	\$1260 (€1096)
Full-Time Government and Academia Member	\$770 (€670)	\$995 (€865)	\$920 (€800)	\$1145 (€996)
Patient Representative	\$330 (€287)	\$415 (€361)	\$480 (€417)	\$565 (€491)
Full-Time Students	\$270 (€235)	\$365 (€317)	\$420 (€365)	\$515 (€448)
1 Day Registration (per day)	\$600 (€522)	\$825 (€717)	\$700 (€609)	\$925 (€804)
☐ 4 Nov ☐ 5 Nov ☐ 6 Nov				

*All fees are collected and charged in USD. Final Euro amount will vary due to currency exchange rate fluctuations at time of purchase.*

**Register at [www.ispor.org/Europe2019reg](http://www.ispor.org/Europe2019reg)**

### EXHIBITOR/SPONSOR OPPORTUNITIES

ISPOR Europe will attract more than 5000 international healthcare leaders and stakeholders. Partner with ISPOR as an exhibitor and sponsor for the opportunity to further connect, network, and collaborate with this influential audience of healthcare decision makers, regulators, payers, researchers, and patient representatives. Ask about the new ISPOR Exhibitor HEOR Theater located in the Poster Exhibit Hall. These 30-minute insightful, informative, and educational sessions presented by Exhibiting Companies and are open to all delegates.

### VENUE INFORMATION

ISPOR Europe 2019 will be held at the Bella Center Copenhagen, centrally located in the heart of Ørestad, with its own Metro station. Bella Center Copenhagen is just 4 miles (6 kilometers) from Copenhagen Airport and 5 miles (8 kilometers) from Copenhagen's City Centre.

**Learn more at [www.ispor.org/Europe2019venue](http://www.ispor.org/Europe2019venue)**

ISPOR-The professional society for health economics and outcomes research  
505 Lawrence Square Blvd, South  
Lawrenceville, NJ 08648 USA

# ISPOR Europe 2019

*Register by 24 September and SAVE!*

*Digital Transformation of Healthcare:  
Changing Roles and Sharing  
Responsibilities*

**FEATURED SESSION**  
**ISPOR Ideas Lab — New Insights to Improve Decision-Making for  
Health Globally**

The ISPOR Ideas Lab is designed to fuel original views and fresh perspectives and to trigger and strengthen innovative thinking and the spirit of discovery in the HEOR Community. Topics include new thinking on “social determinants” and alternative perspective on the “O” and the “E” in HEOR, sustainability index to futureproof healthcare, and next generation HTA for complex and personalized combination of health technologies.

